Dynavax Technologies Shares Outstanding 2006-2021 | DVAX

Dynavax Technologies shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Dynavax Technologies Annual Shares Outstanding
(Millions of Shares)
2020 102
2019 72
2018 62
2017 53
2016 39
2015 33
2014 26
2013 20
2012 17
2011 13
2010 8
2009 4
2008 4
2007 4
2006 3
2005 3
Dynavax Technologies Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 117
2021-06-30 119
2021-03-31 113
2020-12-31 102
2020-09-30 112
2020-06-30 97
2020-03-31 86
2019-12-31 72
2019-09-30 75
2019-06-30 65
2019-03-31 64
2018-12-31 62
2018-09-30 63
2018-06-30 62
2018-03-31 62
2017-12-31 53
2017-09-30 58
2017-06-30 50
2017-03-31 42
2016-12-31 39
2016-09-30 39
2016-06-30 38
2016-03-31 38
2015-12-31 33
2015-09-30 37
2015-06-30 29
2015-03-31 27
2014-12-31 26
2014-09-30 26
2014-06-30 26
2014-03-31 26
2013-12-31 20
2013-09-30 18
2013-06-30 18
2013-03-31 18
2012-12-31 17
2012-09-30 18
2012-06-30 17
2012-03-31 16
2011-12-31 13
2011-09-30 12
2011-06-30 12
2011-03-31 12
2010-12-31 8
2010-09-30 9
2010-06-30 8
2010-03-31 5
2009-12-31 4
2009-09-30 4
2009-06-30 4
2009-03-31 4
2008-12-31 4
2008-09-30 4
2008-06-30 4
2008-03-31 4
2007-12-31 4
2007-09-30 4
2007-06-30 4
2007-03-31 4
2006-12-31 3
2006-09-30 3
2006-06-30 3
2006-03-31 3
2005-12-31 3
2005-09-30 2
2005-06-30 2
2005-03-31 3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.623B $0.047B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69